drugset / Trial / NCT00141700
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is being conducted to determine the safety, side effects, and response to a combination of an established high-dose chemotherapy regimen, stem cell support and Rituximab (which is a form of immunotherapy).
Timeline
- Start
- 2003-03
- Primary completion
- 2005-03
- Completion
- 2005-12
Outcome
Outcome not reported
Stopped (Enrollment): “enrollment completed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | — | — |